YaoKang Biotech: Net profit of 144 million yuan in 2025, a year-on-year increase of 31.49%

2026-02-04 20:53:18

YaoKang Biotech Releases Performance Brief, Achieving Operating Revenue of 793 million yuan in 2025, a year-on-year increase of 15.49%; net profit of 144 million yuan, a year-on-year increase of 31.49%. During the reporting period, the company focused on two core strategies: internationalization and innovation, continuously expanding overseas markets, maintaining high-intensity R&D investment, and keeping its technology and products at the industry forefront. While strengthening its main business, the company also leveraged universal underlying technologies to develop new platforms such as the all-human antibody platform and microbiome research platform, accelerating the transformation of R&D achievements and providing new growth points for the company’s development.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.